Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA, 19104, USA.
Division for Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):623-641. doi: 10.1007/s00259-020-04926-4. Epub 2020 Jul 21.
Positron emission tomography (PET) has been widely utilized in the study of traumatic brain injury (TBI) for decades. While most applications of PET have attempted to assess neuronal function after TBI, more recently, novel radiotracers have sought to image biomarkers in the context of TBI and chronic traumatic encephalopathy (CTE).
This review will begin with an overview of TBI and CTE along with the acute and chronic pathophysiological consequences of TBI. Next, glycolysis, beta-amyloid, and tau protein radiotracers will be critically assessed in light of the most recent imaging studies available.
Based on the scientific relevance of such radiotracers to the molecular processes of TBI and CTE along with the broader evidence of radiotracer specificity and selectivity, this review will weigh the strengths and weaknesses of each radiotracer. Nonetheless, the evidence indicates that PET will continue to be a powerful modality in the diagnosis of TBI-related conditions.
正电子发射断层扫描(PET)在创伤性脑损伤(TBI)的研究中已经被广泛应用了数十年。虽然 PET 的大多数应用都试图评估 TBI 后的神经元功能,但最近,新型放射性示踪剂试图在 TBI 和慢性创伤性脑病(CTE)的背景下成像生物标志物。
本综述将首先概述 TBI 和 CTE 以及 TBI 的急性和慢性病理生理后果。接下来,将根据最新的影像学研究,对糖酵解、β-淀粉样蛋白和tau 蛋白放射性示踪剂进行批判性评估。
基于这些放射性示踪剂与 TBI 和 CTE 的分子过程的科学相关性,以及放射性示踪剂特异性和选择性的更广泛证据,本综述将权衡每种放射性示踪剂的优缺点。尽管如此,证据表明 PET 将继续成为诊断 TBI 相关疾病的有力手段。